A retrospective cohort compared new initiators of three glucose-lowering therapies among 58,754 adults aged 65 and over with type 2 diabetes, 2018-2026. A BMI of 30 or above was present in 72.1% of GLP-1 initiators, as compared to 41.9% of SGLT2 initiators. Those starting GLP-1 drugs also had less dementia, heart failure and renal disease, while average HbA1c was similar across the three groups.
Why it is interesting: Shows which older patients receive GLP-1 drugs, and which conditions point prescribing towards the alternatives.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.